As of Q4'25 (2025-12-31), Pfizer (PFE) reported a net income of -1.65B USD, marking a return to negative territory after several quarters of positive results. The year-over-year (YoY) change for this quarter was -501.95%, indicating a significant decline compared to the same period last year. Over the period from Q1'23 to Q4'25, Pfizer's net income demonstrated considerable volatility, with notable swings between positive and negative values. After a steep decline and consecutive losses in late 2023, the company rebounded in 2024 with positive net income peaking at 4.47B USD in Q3'24, accompanied by a strong YoY surge of 287.45%. However, this recovery was short-lived, as net income dropped sharply again by Q4'25, highlighting ongoing instability in profitability and significant fluctuations in year-over-year performance throughout the observed quarters.